

Clinical trials of betrixaban

TrialResults-center www.trialresultscenter.org

1 thrombosis prevention

Trial	Treatments	Patients	Trials design and methods
betrixaban vs enoxaparin			
APEX , 2016 [NCT01583218] n=3759/3754 follow-up:	betrixaban (at a dose of 80 mg once daily) for 35 to 42 days versus subcutaneous enoxaparin (at a dose of 40 mg once daily) for 104 days	Patients who were hospitalized for acute medical illnesses and with an elevated d-dimer level	Parallel groups double-blind

More details and results :

- antithrombotics for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q87>
- direct oral anticoagulant (DAO) for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q485>

References

APEX, 2016:

Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med 2016 May 27; [27232649]

Entry terms: PRT054021,